Eagle Net Debt from 2010 to 2026

EGRX Stock

USD 0.25 0.00 0.00%

Eagle Pharmaceuticals Net Debt yearly trend continues to be fairly stable with very little volatility. Net Debt is likely to outpace its year average in 2026. Net Debt is the total debt of Eagle Pharmaceuticals minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2012-09-30

Previous Quarter

54.4 M

Current Value

56.3 M

Quarterly Volatility

37.2 M

Yuan Drop

Covid

Interest Hikes

Check Eagle Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eagle Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.5 M, Interest Expense of 4.9 M or Selling General Administrative of 118.5 M, as well as many indicators such as Price To Sales Ratio of 1.3, Dividend Yield of 0.0 or PTB Ratio of 1.77. Eagle financial statements analysis is a perfect complement when working with Eagle Pharmaceuticals Valuation or Volatility modules.

Build AI portfolio with Eagle Stock

Check out the analysis of Eagle Pharmaceuticals Correlation against competitors.

For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.

The evolution of Net Debt for Eagle Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Eagle Pharmaceuticals compares to historical norms and industry peers.

Latest Eagle Pharmaceuticals' Net Debt Growth Pattern

Below is the plot of the Net Debt of Eagle Pharmaceuticals over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Eagle Pharmaceuticals' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eagle Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Net Debt

Timeline

Eagle Net Debt Regression Statistics

	Arithmetic Mean	(23,808,949)
	Coefficient Of Variation	(152.46)
	Mean Deviation	32,451,101
	Median	(10,455,565)
	Standard Deviation	36,300,296
	Sample Variance	1317.7T
	Range	91.6M
	R-Value	0.14
	Mean Square Error	1376.8T
	R-Squared	0.02
	Significance	0.58
	Slope	1,028,572
	Total Sum of Squares	21083.4T

Eagle Net Debt History

	2026	11.8 M
	2025	11.2 M
	2022	12.5 M
	2021	-72.1 M
	2020	-66.1 M
	2019	-71.2 M
	2018	-34.4 M

Other Fundumenentals of Eagle Pharmaceuticals

Net Debt To E B I T D A

Eagle Pharmaceuticals Net Debt component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Tangible Assets	Good Will	Capital Surpluse	Intangible Assets	Long Term Debt Total	Net Invested Capital	Short Long Term Debt	Net Working Capital	Capital Stock
Total Assets		0.91	0.82	0.17	0.95	0.94	0.92	0.98	-0.23	0.96	0.88	0.13	0.82	0.3	0.57	0.34	0.92	0.74	0.46	0.65	0.25	-0.84	0.71
Total Stockholder Equity	0.91		0.89	-0.09	0.9	0.82	0.83	0.91	-0.23	0.8	0.98	0.14	0.92	0.38	0.66	0.3	0.95	0.5	0.41	0.57	0.25	-0.74	0.53
Current Deferred Revenue	0.82	0.89		0.07	0.92	0.73	0.85	0.81	-0.16	0.75	0.84	0.35	0.72	0.12	0.57	0.54	0.93	0.49	0.42	0.52	0.38	-0.77	0.52
Net Debt	0.17	-0.09	0.07		0.11	0.26	0.21	0.12	0.14	0.42	-0.22	-0.04	-0.28	-0.56	-0.64	0.52	0.11	0.76	0.5	0.64	-0.25	-0.49	0.53
Retained Earnings	0.95	0.9	0.92	0.11		0.85	0.94	0.94	-0.2	0.89	0.88	0.29	0.77	0.25	0.65	0.47	0.93	0.62	0.34	0.52	0.36	-0.8	0.59
Accounts Payable	0.94	0.82	0.73	0.26	0.85		0.88	0.9	-0.21	0.93	0.76	0.28	0.74	0.25	0.41	0.39	0.85	0.77	0.64	0.66	0.37	-0.87	0.71
Long Term Debt	0.92	0.83	0.85	0.21	0.94	0.88		0.9	-0.16	0.91	0.83	0.36	0.7	0.23	0.55	0.44	0.89	0.68	0.52	0.57	0.44	-0.86	0.66
Net Receivables	0.98	0.91	0.81	0.12	0.94	0.9	0.9		-0.25	0.93	0.89	0.06	0.83	0.36	0.61	0.31	0.89	0.67	0.37	0.59	0.19	-0.78	0.66
Short Term Investments	-0.23	-0.23	-0.16	0.14	-0.2	-0.21	-0.16	-0.25		-0.19	-0.25	0.01	-0.1	-0.43	-0.34	0.19	-0.2	-0.01	-0.02	-0.04	-0.03	0.06	-0.06
Total Liab	0.96	0.8	0.75	0.42	0.89	0.93	0.91	0.93	-0.19		0.75	0.11	0.67	0.14	0.35	0.41	0.87	0.89	0.58	0.78	0.17	-0.9	0.81
Total Current Assets	0.88	0.98	0.84	-0.22	0.88	0.76	0.83	0.89	-0.25	0.75		0.13	0.94	0.48	0.76	0.17	0.91	0.38	0.32	0.45	0.29	-0.66	0.46
Short Term Debt	0.13	0.14	0.35	-0.04	0.29	0.28	0.36	0.06	0.01	0.11	0.13		0.11	-0.18	0.22	0.35	0.27	0.01	0.33	-0.1	0.91	-0.34	0.05
Common Stock	0.82	0.92	0.72	-0.28	0.77	0.74	0.7	0.83	-0.1	0.67	0.94	0.11		0.42	0.71	0.09	0.82	0.33	0.27	0.39	0.26	-0.58	0.42
Property Plant Equipment	0.3	0.38	0.12	-0.56	0.25	0.25	0.23	0.36	-0.43	0.14	0.48	-0.18	0.42		0.63	-0.12	0.14	-0.18	-0.2	-0.18	-0.01	0.15	-0.09
Net Tangible Assets	0.57	0.66	0.57	-0.64	0.65	0.41	0.55	0.61	-0.34	0.35	0.76	0.22	0.71	0.63		-0.1	0.56	-0.1	-0.21	-0.15	0.46	-0.19	0.07
Good Will	0.34	0.3	0.54	0.52	0.47	0.39	0.44	0.31	0.19	0.41	0.17	0.35	0.09	-0.12	-0.1		0.37	0.49	0.31	0.4	0.09	-0.44	0.39
Capital Surpluse	0.92	0.95	0.93	0.11	0.93	0.85	0.89	0.89	-0.2	0.87	0.91	0.27	0.82	0.14	0.56	0.37		0.63	0.53	0.68	0.35	-0.88	0.66
Intangible Assets	0.74	0.5	0.49	0.76	0.62	0.77	0.68	0.67	-0.01	0.89	0.38	0.01	0.33	-0.18	-0.1	0.49	0.63		0.66	0.88	-0.03	-0.85	0.84
Long Term Debt Total	0.46	0.41	0.42	0.5	0.34	0.64	0.52	0.37	-0.02	0.58	0.32	0.33	0.27	-0.2	-0.21	0.31	0.53	0.66		0.75	0.29	-0.76	0.64
Net Invested Capital	0.65	0.57	0.52	0.64	0.52	0.66	0.57	0.59	-0.04	0.78	0.45	-0.1	0.39	-0.18	-0.15	0.4	0.68	0.88	0.75		-0.16	-0.81	0.85
Short Long Term Debt	0.25	0.25	0.38	-0.25	0.36	0.37	0.44	0.19	-0.03	0.17	0.29	0.91	0.26	-0.01	0.46	0.09	0.35	-0.03	0.29	-0.16		-0.35	0.05
Net Working Capital	-0.84	-0.74	-0.77	-0.49	-0.8	-0.87	-0.86	-0.78	0.06	-0.9	-0.66	-0.34	-0.58	0.15	-0.19	-0.44	-0.88	-0.85	-0.76	-0.81	-0.35		-0.76
Capital Stock	0.71	0.53	0.52	0.53	0.59	0.71	0.66	0.66	-0.06	0.81	0.46	0.05	0.42	-0.09	0.07	0.39	0.66	0.84	0.64	0.85	0.05	-0.76

Click cells to compare fundamentals

About Eagle Pharmaceuticals Financial Statements

Eagle Pharmaceuticals investors use historical fundamental indicators, such as Eagle Pharmaceuticals' Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Eagle Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	11.2 M	11.8 M
Net Debt To EBITDA	0.16	0.19

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

FSLY	Fastly Class A
MOB	Mobilicom Limited American
CMG	Chipotle Mexican Grill

Additional Tools for Eagle Stock Analysis

When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Eagle Net Debt from 2010 to 2026

Latest Eagle Pharmaceuticals' Net Debt Growth Pattern

Eagle Net Debt Regression Statistics

Eagle Net Debt History

Other Fundumenentals of Eagle Pharmaceuticals

Eagle Pharmaceuticals Net Debt component correlations

About Eagle Pharmaceuticals Financial Statements

Also Currently Popular

Additional Tools for Eagle Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY